Targacept Files for Initial Public Offering
05/14/2004
Winston-Salem, NC - Targacept, Inc. today announced that it has filed a
registration statement on Form S-1 with the Securities and Exchange Commission
for the proposed initial public offering of shares of its common stock. All of
the shares will be issued and sold by Targacept.
The managing underwriter of the offering will be Morgan Stanley, acting as
book-running manager, with Deutsche Bank Securities Inc., CIBC World Markets and
Pacific Growth Equities, LLC as co-managers.
The offering will be made only by means of a prospectus. A copy of the
preliminary prospectus relating to the offering may be obtained, when available,
from Morgan Stanley & Co. Incorporated, Prospectus Department, located at
1585 Broadway, New York, NY 10036, (212) 761-6775.
A registration statement relating to these securities has been filed with the
Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy nor shall
there be any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
About Targacept
Targacept, Inc. is a biopharmaceutical company engaged in the design,
discovery and development of drugs to treat multiple nervous system diseases and
disorders by selectively targeting a class of receptors known as neuronal
nicotinic acetylcholine receptors, or nnrs. Targacept is located in
Winston-Salem, North Carolina. |
